Leleu, Xavier
Martin, Thomas
Weisel, Katja
Schjesvold, Fredrik
Iida, Shinsuke
Malavasi, Fabio
Manier, Salomon
Chang-Ki Min,
Ocio, Enrique M.
Pawlyn, Charlotte
Perrot, Aurore
Quach, Hang
Richter, Joshua
Spicka, Ivan
Yong, Kwee
Richardson, Paul G.
Funding for this research was provided by:
Sanofi
Article History
Received: 26 January 2022
Accepted: 2 July 2022
First Online: 9 August 2022
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Leleu X. declares that he has no conflict of interest. Martin T. has received research funding (to institution) from Amgen, Janssen, and Sanofi, and consulting honoraria from GSK. Weisel K. has received research funding from Amgen, Bristol Myers Squibb/Celgene, GSK, and Sanofi, and honoraria from AbbVie, Amgen, Adaptive Biotech, Bristol Myers Squibb/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda. Schjesvold F. has received research funding from Bristol Myers Squibb/Celgene, Janssen, Oncopeptides, and Sanofi, and honoraria from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GSK, Janssen, Novartis, Oncopeptides, Sanofi, Schain, SkyliteDX, and Takeda. Iida S. has received research funding and honoraria from AbbVie, Amgen, Bristol Myers Squibb/Celgene, Chugai, Daiichi Sankyo, Janssen, Kyowa Kirin, Ono, Sanofi, and Takeda. Malavasi F. declares that he has no conflict of interest. Manier S. has received research funding and consulting honoraria from AbbVie, Adaptive Biotechnology, Amgen, Celgene/Bristol Myers Squibb, GSK, Janssen, Novartis, Oncopeptide, Regeneron, Roche, and Takeda. Min C.-K. declares that she has no conflict of interest. Ocio E. M. has received honoraria from Amgen, Bristol Myers Squibb, GSK, Janssen, Oncopeptides, Pfizer, Sanofi, and Takeda. Pawlyn C. has received honoraria and non-financial support from Amgen, Bristol Myers Squibb/Celgene, Janssen, and Sanofi, and non-financial support from Oncopeptides. Perrot A. has received research funding from Takeda and honoraria from AbbVie, Amgen, Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda. Quach H. has received research funding from Bristol Myers Squibb/Celgene, GSK, Karyopharm, and Sanofi, and advisory board/consulting honoraria from Bristol Myers Squibb/Celgene, GSK, Janssen, Karyopharm, Sanofi, and Takeda. Richter J. has received advisory board/consulting honoraria from Adaptive Biotechnologies, Astra Zeneca, Bristol Myers Squibb/Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura bio, and X4 Pharmaceuticals. Spicka I. has received advisory board/consulting honoraria from Amgen, Bristol Myers Squibb/Celgene, Janssen, Novartis, PharmaMar, Sanofi, and Takeda. Yong K. declares that she has no conflict of interest. Richardson P. G. has received research funding from Bristol Myers Squibb/Celgene, Oncopeptides, and Takeda, and honoraria from Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, and Takeda.